Background: In the InforMing the Pathway of COPD Treatment (IMPACT) trial, single-inhaler
fluticasone furoate (FF)/umeclidinium (UMEC)/vilanterol (VI) significantly reduced severe …

In patients with chronic obstructive pulmonary disease (COPD), cardiovascular
comorbidities are highly prevalent and associated with considerable morbidity and mortality …

Background Differences in previous exacerbation history may influence prognosis of chronic
obstructive pulmonary disease (COPD). We hypothesized that prognosis differs between …

Background Better insight in patients' prognosis can help physicians to timely initiate
advance care planning (ACP) discussions with patients with chronic obstructive pulmonary …

Chronic obstructive pulmonary disease (COPD) has a high prevalence and a major impact
on health-related quality of life (HRQL). COPD exacerbations are an important cause of …

AIM: To assess and compare health status among chronic obstructive pulmonary disease
(COPD) patients presenting for treatment in six countries and in two healthcare settings …

Background COPD is one of the leading causes of morbidity and mortality in the world;
however, the most varied amounts of clinical and laboratory characteristics acts in different …

Background: Chronic obstructive pulmonary disease is a chronic, often progressive disease,
which in most patients is caused by tobacco smoking. Our study focuses on differences in …

Background and Aim Exacerbations of chronic obstructive pulmonary disease (COPD) carry
significant consequences for patients and are responsible for considerable health-care costs …

Chronic obstructive pulmonary disease (COPD) has become a major and growing health
problem, with a mortality rate that continues to increase. Several factors, have been …